Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Upadacitinib
Rinvoq
Routinely available
SMC (SMC2575)
07/06/2023
Indication
For the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent, or for whom such therapies are not advisable.
Therapeutic Area
Gastro-intestinal system
Status Description
Routinely available in line with national guidance
Formulation
15mg, 30mg and 45mg prolonged release tablets
Comments
June 2023 - Routinely available in line with national guidance. Included on the ERF for Specialist Use only.
Link to Advice
Advice Published
12/06/2023
SMC Submission Type
Abbreviated
SMC Status
Accepted